Angiotensin converting enzyme inhibitors are not associated with respiratory complications or mortality after noncardiac surgery.
Selection and isolation of
angiotensin I-converting enzyme inhibitory peptides
Li, Effect of combined ultrasonic and alkali pretreatment on enzymatic preparation of
angiotensin converting enzyme (ACE) inhibitory peptides from native collagenous materials, Ultrason.
Compared with the use of
angiotensin receptor blockers, ACEI use was correlated with an increased risk for lung cancer (incidence rate, 1.6 versus 1.2 per 1,000 person-years; hazard ratio, 1.14).
"Associations were evident after five years of use and increased with longer durations of use, particularly in patients who used
angiotensin converting enzyme inhibitors for more than 10 years."
* XW033H4 Introduction of Synthetic Human
Angiotensin II into Peripheral Vein, Percutaneous Approach, New Technology Group 4
Keywords: Renin
angiotensin aldosterone disorders, Primary hyperaldosteronism, Essential hypertension.
Angiotensin- converting enzyme insertion/deletion (ACE I/D) and
angiotensin II type 1 receptor (AT1R) gene polymorphism and its association with preeclampsia in Chinese women.
The aims of this study were (a) to investigate the impact of contemporary RAS blockade on
angiotensin metabolite concentrations; (b) to correlate ARC with
angiotensin levels and disease severity; and (c) to assess the feasibility of ARC screening in HFrEF patients receiving optimal medical treatment (OMT) for the identification of heart failure phenotypes with low and high RAS activation, possibly unveiling further therapeutic need.
Angiotensin I- and II- and norepinephrine-mediated pressor responses in an ancient Holostean fish, the bowfin (Amia calva).
Caption: Figure 1: Effect of chronic
angiotensin II infusion on IL-22/IL-22R1 protein levels.
In cultured primary cardiomyocytes, PPAR-[alpha] activation inhibited
angiotensin II-induced cardiac hypertrophy and decreased ADAM17 protein and mRNA levels.
In nonpregnant women, angiotensin-converting enzyme inhibitors and
angiotensin II receptor antagonists are popular first-line therapies for primary hypertension.
Renin acts enzymatically on the plasma protein, angiotensinogen, which is converted to
angiotensin I, a mild vasoconstrictor.
